Human FGF receptor and β-Klotho binding proteins
    32.
    发明授权
    Human FGF receptor and β-Klotho binding proteins 有权
    人FGF受体和β-Klotho结合蛋白

    公开(公告)号:US09517264B2

    公开(公告)日:2016-12-13

    申请号:US13641041

    申请日:2011-04-13

    摘要: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    摘要翻译: 本发明提供与抗原结合蛋白和特异性结合β-Klotho或β-Klotho以及FGFR1c,FGFR2c,FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合相关或衍生的组合物和方法。 在一些实施方案中,抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。 在一些实施方案中,抗原结合蛋白或抗原结合蛋白FGF21融合抗原结合组分是完全人,人源化或嵌合抗体,所述抗体的结合片段和衍生物,以及特异性结合β-Klotho或β- Klotho和FGFR1c,FGFR2c,FGFR3c和FGFR4中的一种或多种。 其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸,及其片段和衍生物,以及多肽,包含这种多核苷酸的细胞,制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物, 其衍生物和多肽,以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体,其片段和衍生物和多肽的方法,包括治疗或诊断患有2型糖尿病,肥胖症,NASH,代谢综合征和 相关疾病或病症。

    POLYPEPTIDES AND ANTIBODIES
    36.
    发明申请
    POLYPEPTIDES AND ANTIBODIES 审中-公开
    多肽和抗体

    公开(公告)号:US20130101589A1

    公开(公告)日:2013-04-25

    申请号:US13607384

    申请日:2012-09-07

    IPC分类号: A61K39/395

    摘要: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

    摘要翻译: 提供多肽。 提供结合这些多肽的抗体或抗原结合结构域。 还提供了获得结合肿瘤坏死因子(TNF)相关的凋亡诱导配体(“TRAIL”)受体-2(TR-2)的抗体的方法,包括向动物施用至少一种这样的多肽并获得抗体 其结合来自动物的TR-2。 提供与TR-2反应的抗体。 还提供产生与TR-2反应的抗体的细胞,包含与TR-2反应的抗体的药物组合物,使用与TR-2反应的抗体的方法,以及包含与TR-2反应的抗体的试剂盒。 还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。